期刊文献+

阿托伐他汀钙联合黄芪辅助治疗早期糖尿病肾病的临床研究 被引量:8

Clinical Research of Atorvastatin Calcium Combined Astragalus Auxiliary Treatment on Early Diabetic Nephropathy
下载PDF
导出
摘要 目的:探讨阿托伐他汀钙联合黄芪对早期糖尿病肾病患者肾功能及血清炎症细胞因子水平的影响。方法:将80例符合标准的患者随机分为观察组和对照组各40例,两组患者均给予糖尿病饮食、控制血糖等治疗,观察组加用阿托伐他汀钙胶囊和黄芪。结果:两组患者治疗前,UAER、24h尿蛋白定量和Cr,以及血清CRP、IL-6和TNF-α水平比较,差异均无统计学意义(P>0.05);疗程结束后,两组患者较治疗前上述指标水平均下降(P<0.05),但是观察组患者下降幅度更显著(P<0.05)。观察组患者临床总有效率87.50%,明显高于对照组的40.00%,差异存在统计学意义(P<0.05)。结论:阿托伐他汀联合黄芪辅助治疗早期糖尿病肾病,具有减轻微量白蛋白尿和肾脏保护作用,值得临床推广应用。 Objective: To investigate the effects of atorvastatin calcium combined with astragalus on ear- ly diabetic nephropathy patients with renal function and serum levels of inflammatory cytokines influence. Method: 80 patients with standard were randomly divided into the observation group and the control group with 40 cases in each group, the patients in two groups were given a diabetic diet, controlled of blood glucose and other treatment, the observation group with atorvastatin calcium capsules and astragalus. Result: The UAER, 24h urine protein and Cr, and serum CRP, IL-6 and TNF-a level were compared, there were no significant differences between them ( P 〉0. 05 ) ; after the end of treatment, indexes were decreased ( P 〈 0.05), but the patients in the observation group ( P 〈0. 05 ) was more significant. The total effective rate was 87.50% of the patients in the observation group , h was significantly higher than that of control group, There's statistically significant difference ( P 〈 0.05 ). Conclusion. Effect of atorvastatin combined with as- tragalus adjuvant treatment of early- diabetic nephropathy with ease, microalbuminuria and renal protective effects, it is worthy of clinical application.
作者 唐晓君
出处 《河北医学》 CAS 2013年第4期492-495,共4页 Hebei Medicine
关键词 糖尿病肾病 炎症细胞因子 阿托伐他汀钙 黄芪 Diabetic nephropathy Inflammatory cytokines Atorvastatin calcium Astragalus
  • 相关文献

参考文献9

  • 1杨爱成,魏连波,肖炜,梁炜,袁申平,柳文晶,张颖,姜斌.肾康丸与阿托伐他汀对早期糖尿病肾病患者炎症因子影响的比较[J].广东医学,2009,30(5):804-807. 被引量:13
  • 2Megesen CE, Chrietenzen CK. The diabetic kidney from nyperfifation and mictoaUumin to end- stage renal failure [J]. Med Clin Nor Am, 1998, 72(8) : 1465-1467.
  • 3王志祥,韩艳.阿托伐他汀辅助治疗早期糖尿病肾病疗效分析[J].中国医药科学,2011,1(10):89-89. 被引量:7
  • 4Dronavalli S, Duka I, Bakris GL. The pathogenesis of dia- betic nephropathy [ J ]. Nat Clin Pract Endocrinol Metab, 2008, 4(8) : 444-452.
  • 5方勤.糖尿病肾病发病机制的研究进展[J].中国实用内科杂志,1999,19(4):239-240. 被引量:104
  • 6Clodim, Oberbauerr, Bodlajg, et al. Urinary excretion of apolipoprotein(a) fragments in type I diabetes mellitus pa- tients [ J ]. Metabolism, 1999, 48 (3) : 369-372.
  • 7HU F B, MEIGS J B, LITY, et al. Inflammatory markers and risk of developing type 2 diabetes in women[ J]. Diabe- tes, 2004, 53(3): 693-700.
  • 8Furaya D T, Poletto A C, Favaro R R, et al. Anti-inflam- matory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice[ J]. Metabolism, 2010, 59(3) : 395-399.
  • 9Riad A, Du J, Stiehl S. Low-dose treatment with atorvasta- tin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus [ J ]. Eur Pharmacol, 2007, 569 (3) : 204- 211.

二级参考文献16

  • 1陈路燕,高彦彬,赵东英,徐进广.益气养阴补肾活血方剂治疗早期糖尿病肾病的临床研究[J].中国中医基础医学杂志,2005,11(10):767-769. 被引量:11
  • 2陈国宝,魏连波,龙海波.肾康丸治疗早期糖尿病肾病的临床研究[J].浙江中医杂志,2006,41(5):260-261. 被引量:17
  • 3ANONYMOUS.Incidence and prevalence of ESRD[J].Am J Kidney Dis,1999,34(2 Suppl 1)S40-S50.
  • 4World Health Organization.Definition,diagnosis and classifica -tion of diabetes mellitus and its complications.Report of a WHO consultation[J].Geneva:World Health Organization,1999.
  • 5PICKUP J C,CROOK M A.Is type Ⅱ diabetes mellitus a disease of theinnate immune system?[J].Diabetologia,1998,41(10):1241-1248.
  • 6FERNANDEZ REAL J M,RICART W.Insulin resistance and inflammation in an evolutionary perspective:the contribution of cytokine geno-type/phenotype to thriftness[J].Diabetologia,1999,42(1):1 367-1 374.
  • 7CLODI M,OBERBAUER R,BODLAJ G,et al.Urinary excretion of apolipoprotein(a) fragments in type 1 diabetes mellitns patients[J].Metabolism,1999,48(3):369-372.
  • 8WELLEN K E,HOTAMISLIGIL G S.Inflammation,stress,and diabetes[J].J Clin Invest,2005,115 (5):1111-1119.
  • 9HU F B,MEIGS J B,LIT Y,et al.Inflammatory markers and risk of developing type 2 diabetes in women[J].Diabetes,2004,53(3):693-700.
  • 10VIEDT C,DECHEND R,FEI J,et al.MCP-1 induces inflammatoryactivation of human tubular epithelial cells:involvement of the transcription factors,nuclear factor-κB and activating protein-1[J].Am Soc Nephrol,2002,13(6):1 534-1 547.

共引文献120

同被引文献79

引证文献8

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部